Search Results - "Greenfelder, Brian"

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 by Evering, Teresa H, Chew, Kara W, Giganti, Mark J, Moser, Carlee, Pinilla, Mauricio, Wohl, David Alain, Currier, Judith S, Eron, Joseph J, Javan, Arzhang Cyrus, Bender Ignacio, Rachel, Margolis, David, Zhu, Qing, Ma, Ji, Zhong, Lijie, Yan, Li, D'Andrea Nores, Ulises, Hoover, Keila, Mocherla, Bharat, Choudhary, Manish C, Deo, Rinki, Ritz, Justin, Fischer, William A, Fletcher, Courtney V, Li, Jonathan Z, Hughes, Michael D, Smith, Davey, Daar, Eric S

“…Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal…”
Get full text

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection by Deo, Rinki, Choudhary, Manish C, Moser, Carlee, Ritz, Justin, Daar, Eric S, Wohl, David A, Greninger, Alexander L, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, Chew, Kara W, Li, Jonathan Z

“…Although symptom and viral rebound have been reported after nirmatrelvir-ritonavir treatment, the trajectories of symptoms and viral load during the natural…”
Get full text

Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial by Chew, Kara W, McGinley, Brooke, Moser, Carlee, Li, Jonathan Z, Evering, Teresa H, Ritz, Justin, Javan, Arzhang Cyrus, Margolis, David, Wohl, David A, Hughes, Michael D, Daar, Eric S, Currier, Judith S, Eron, Joseph J, Smith, Davey M

“…We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial…”
Get full text

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial by Chew, Kara W, Taiwo, Babafemi O, Moser, Carlee, Daar, Eric S, Wohl, David Alain, Ritz, Justin, Javan, Arzhang Cyrus, Li, Jonathan Z, Fischer, William, Greninger, Alexander L, Bausch, Christoph, Luke, Thomas, Call, Robert, Neytman, Gene, Giganti, Mark J, Fletcher, Courtney V, Hughes, Michael D, Eron, Joseph J, Currier, Judith S, Smith, Davey M, Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Hughes, Michael, Moser, Carlee, Giganti, Mark, Ritz, Justin, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Beck, Justine, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Kosmyna, Jan, Gapara, Morgan, Shahkolahi, Akbar

“…Abstract Background We evaluated the fully human polyclonal antibody product SAB-185 in a phase 3 trial for COVID-19. Methods Nonhospitalized high-risk adults…”
Get full text

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial by Jilg, Nikolaus, Chew, Kara W, Giganti, Mark J, Daar, Eric S, Wohl, David A, Javan, Arzhang Cyrus, Kantor, Amy, Moser, Carlee, Coombs, Robert W, Neytman, Gene, Hoover, Keila, Jana, Atasi, Hart, Phil A, Greninger, Alexander L, Szurgot, Bob, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, Li, Jonathan Z

“…Abstract Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of…”
Get full text

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial by Choudhary, Manish C., Chew, Kara W., Deo, Rinki, Flynn, James P., Regan, James, Crain, Charles R., Moser, Carlee, Hughes, Michael D., Ritz, Justin, Ribeiro, Ruy M., Ke, Ruian, Dragavon, Joan A., Javan, Arzhang Cyrus, Nirula, Ajay, Klekotka, Paul, Greninger, Alexander L., Fletcher, Courtney V., Daar, Eric S., Wohl, David A., Eron, Joseph J., Currier, Judith S., Parikh, Urvi M., Sieg, Scott F., Perelson, Alan S., Coombs, Robert W., Smith, Davey M., Li, Jonathan Z.

“…SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. However, it remains unclear whether in vivo emergence of…”
Get full text

Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19 by Smith, Davey M, Li, Jonathan Z, Moser, Carlee, Yeh, Eunice, Currier, Judith S, Chew, Kara W, Hughes, Michael D

“…This cohort study of US adults with untreated COVID-19 examines the types and length of symptoms experienced following symptom recurrence…”
Get full text

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialResearch in context by Teresa H. Evering, Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li, David Margolis, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Eric S. Daar, Davey M. Smith, Michael D. Hughes, Kara W. Chew, Kara Chew, David (Davey) Smith, Eric Daar, David Wohl, Judith Currier, Joseph Eron, Arzhang Cyrus Javan, Michael Hughes, Carlee Moser, Mark Giganti, Justin Ritz, Lara Hosey, Jhoanna Roa, Nilam Patel, Kelly Colsh, Irene Rwakazina, Justine Beck, Scott Sieg, Jonathan Li, Courtney Fletcher, William Fischer, Teresa H. Evering, Rachel Bender Ignacio, Sandra Cardoso, Katya Corado, Prasanna Jagannathan, Nikolaus Jilg, Alan Perelson, Sandy Pillay, Cynthia Riviere, Upinder Singh, Babafemi Taiwo, Joan Gottesman, Matthew Newell, Susan Pedersen, Joan Dragavon, Cheryl Jennings, Brian Greenfelder, William Murtaugh, Jan Kosmyna, Morgan Gapara, Akbar Shahkolahi, David Margolis, Verónica Lacal, Diego Salusso, Sebastian Nuñez, Marcelo Rodrigo Rodriguez, Luciana Laborde, Marcelo Papasidero, Luis Wehbe, Mariana Gonzalez, Felicitas Fernandez Voena, Tomas Alvarez, Amaru Lopez, Virginia Huhn, Ulises D'Andrea Nores, Pablo Dieser, Fernando Bordese, Marisa Mussi, Rodrigo de Carvalho Santana, Adriana Aparecida Tiraboschi Bárbaro, Breno Santos, Rita de Cássia Alves Lira, Andre Luiz Machado da Silva, Sandra Wagner Cardoso, Maria Pia Diniz Ribeiro, Nathália Soliva, Eduardo Vasconcellos, Jorge Eurico Ribeiro, Miriam Amaral Enéas, Jorge Pinto, Julia Fonseca de Morais Caporali, Flávia Gomes Faleiro Ferreira, Norma Erendira Rivera Martinez, Victor Casildo Bohorquez Lopez, Melchor Victor Frias, Krystle Fetalvero, Alyxzza Maranan, Jennifer Rosa, Thomas Coetzer, Maureen Mohata, Sr, Umesh Lalloo, Penelope Madlala, Larisha Pillay-Ramaya, Jaclyn Ann Bennet, Noluthando Mwelase

“…Background: It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously…”
Get full text

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial by Ritz, Justin, Li, Jonathan Z., Wohl, David, Giganti, Mark, Patel, Nilam, Colsh, Kelly, Evering, Teresa H., Ignacio, Rachel Bender, Jilg, Nikolaus, Perelson, Alan, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Gapara, Morgan, Margolis, David, Nuñez, Sebastian, Papasidero, Marcelo, Wehbe, Luis, Voena, Felicitas Fernandez, Lopez, Amaru, Huhn, Virginia, Dieser, Pablo, Mussi, Marisa, de Carvalho Santana, Rodrigo, Tiraboschi Bárbaro, Adriana Aparecida, Santos, Breno, Cardoso, Sandra Wagner, Diniz Ribeiro, Maria Pia, Vasconcellos, Eduardo, Faleiro Ferreira, Flávia Gomes, Bohorquez Lopez, Victor Casildo, Coetzer, Thomas, Madlala, Penelope, Petrick, Frederick, Mbali, Rose, Zwane, Zinhle, Chiperera, Tendai, Mohapi, Lerato, Singh, Usha, McHarry, Kirsten, Snyman, Elizma, Adonis, Tania, Sein, Ni Ni, Mitha, Ismail, Lummus, Christie, Kim, Andrew, Kao, Wei-Hsin, Pfeffer, Michael M., Arnold, Melanie, Karpf, Cinzia, Yawetz, Sigal, Keenan, Cheryl, Milstone, Aaron, Berardi, Jonathan, Arar, Celine, Gomez-Martinez, Marissa, Focil, Augusto, Rosas, Griselda, Bukhman, Eugene, Farah, Humam, Kingsley, Jeffrey, Herman, Craig, Leon, Ramon, Nikolov, Boris, Jagizarov, Zarema, Becker, Becky, Maldonado, Valarie, Veltman, Jennifer, Pullman, John, Johnson, Misty, Hecker, Michelle, Wernick, Arthur, Ruiz, Karelia, Harber, Heather, Cicarella, Robyn, Pulliam, Sallie D., Socorro, Estefania, Neytman, Gene, Aziz, Mariam, Swiatek, Joan, Hoover, Susan E., Weston, Patrick, Sullivano, Jennifer, Clemency, Brian, Khodabakhshian, Aleen, Fortier, Samantha, Rathore, Mobeen, Mahmoudi, Saniyyah, Spikes, Leslie, Hall, Chase, Loftis, Amy James, Short, William, Mendez, Luis M., Jonsson, Chris, Nakatani, Lisa, Williamson, Derrick, Atriss, Hisham, Caloura, Matthew, Presti, Rachel

“…It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated…”
Get full text

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial by Jagannathan, Prasanna, Giganti, Mark J., Hughes, Michael D., Moser, Carlee, Main, Mark J., Monk, Phillip D., Javan, Arzhang Cyrus, Fletcher, Courtney V., McCarthy, Caitlyn, Wohl, David A., Daar, Eric S., Eron, Joseph J., Singh, Upinder, Smith, Davey M., Fischer, William, Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Moser, Carlee, Giganti, Mark, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Gapara, Morgan, Shahkolahi, Akbar, Main, Mark J., Pierone, Gerald, Elliott, Juliana, Jacobson, Jeffrey, Hojat, Leila, Pasternak, Julie, Berardi, Jonathan, Arar, Celine, Bukhman, Yevgeniy, Jain, Manish, Bukhman, Eugene, Shaik, Sadia, Hatlen, Timothy, Dooley, Kelly, Wilkins, Adaliah, Pérez, Jose, Fernández, Heriberto, Hoover, Keila, Renfroe, James, Weldon, Mauney, Bougher, Genei, Malvestutto, Carlos, Harber, Heather, Cicarella, Robyn, Neytman, Gene, Herman, Jack, Herman, Craig, Swiatek, Joan, Pathak, Divya, Choudhary, Madhu, Sullivano, Jennifer, Torna, Odelsey, Khodabakhshian, Aleen, Benson, Constance, Hendrickx, Steven, Luetkemeyer, Anne, Dentoni-Lasofsky, Dennis, Spikes, Leslie, Hall, Chase, Oakes, Jonathan, Loftis, Amy James, Tebas, Pablo, Short, William, McGuffin, Sarah, Jonsson, Chris, Presti, Rachel, Haile, Alem

“…With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel…”
Get full text

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials by Bender Ignacio, Rachel A, Chew, Kara W, Moser, Carlee, Currier, Judith S, Eron, Joseph J, Javan, Arzhang Cyrus, Giganti, Mark J, Aga, Evgenia, Gibbs, Michael, Tchouakam Kouekam, Hervé, Johnsson, Eva, Esser, Mark T, Hoover, Keila, Neytman, Gene, Newell, Matthew, Daar, Eric S, Fischer, William, Fletcher, Courtney V, Li, Jonathan Z, Greninger, Alexander L, Coombs, Robert W, Hughes, Michael D, Smith, Davey, Wohl, David Alain

“…Development of effective, scalable therapeutics for SARS-CoV-2 is a priority. To test the efficacy of combined tixagevimab and cilgavimab monoclonal antibodies…”
Get full text

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialResearch in context by Prasanna Jagannathan, Kara W. Chew, Mark J. Giganti, Michael D. Hughes, Carlee Moser, Mark J. Main, Phillip D. Monk, Arzhang Cyrus Javan, Jonathan Z. Li, Courtney V. Fletcher, Caitlyn McCarthy, David A. Wohl, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Upinder Singh, Davey M. Smith, William Fischer, Kara Chew, David (Davey) Smith, Eric Daar, David Wohl, Judith Currier, Joseph Eron, Arzhang Cyrus Javan, Michael Hughes, Carlee Moser, Mark Giganti, Justin Ritz, Lara Hosey, Jhoanna Roa, Nilam Patel, Kelly Colsh, Irene Rwakazina, Justine Beck, Scott Sieg, Jonathan Li, Courtney Fletcher, William Fischer, Teresa Evering, Rachel Bender Ignacio, Sandra Cardoso, Katya Corado, Prasanna Jagannathan, Nikolaus Jilg, Alan Perelson, Sandy Pillay, Cynthia Riviere, Upinder Singh, Babafemi Taiwo, Joan Gottesman, Matthew Newell, Susan Pedersen, Joan Dragavon, Cheryl Jennings, Brian Greenfelder, William Murtaugh, Jan Kosmyna, Morgan Gapara, Akbar Shahkolahi, Mark J. Main, Gerald Pierone, Juliana Elliott, Jeffrey Jacobson, Leila Hojat, Julie Pasternak, Jonathan Berardi, Celine Arar, Yevgeniy Bukhman, Manish Jain, Eugene Bukhman, Sadia Shaik, Timothy Hatlen, Kelly Dooley, Becky Becker, Adaliah Wilkins, Jose Pérez, Eloy Roman, Heriberto Fernández, Keila Hoover, James Renfroe, Mauney Weldon, Genei Bougher, Carlos Malvestutto, Heather Harber, Robyn Cicarella, Gene Neytman, Jack Herman, Craig Herman, Mariam Aziz, Joan Swiatek, Divya Pathak, Madhu Choudhary, Jennifer Sullivano, Olayemi Osiyemi, Myriam Izquierdo, Odelsey Torna, Aleen Khodabakhshian, Samantha Fortier, Constance Benson

“…Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of…”
Get full text